Hospital Acquired Disease Testing Market – Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Test Type (Molecular, Conventional), By Infection Type (UTI, Pneumonia, Surgical Site Infection, Blood Stream Infections, Others), By Product (Consumables, Instruments), By Type (Blood Tests, Urinalysis), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 5.29 Billion
CAGR (2026-2031)	7.88%
Fastest Growing Segment	Molecular Tests
Largest Market	Europe
Market Size (2031)	USD 8.34 Billion

Market Overview

The Global Hospital Acquired Disease Testing Market will grow from USD 5.29 Billion in 2025 to USD 8.34 Billion by 2031 at a 7.88% CAGR. The Global Hospital Acquired Disease Testing Market comprises diagnostic assays and screening procedures designed to identify infectious agents, such as bacteria and viruses, transmitted to patients within healthcare facilities. The primary drivers propelling market growth include the rising prevalence of nosocomial infections and an expanding geriatric population that is increasingly susceptible to these conditions. Furthermore, stringent government regulations mandating rigorous infection control protocols and the critical implementation of antimicrobial stewardship programs actively support the demand for accurate and rapid diagnostic solutions.

However, a significant challenge hindering broader market expansion is the high cost associated with advanced molecular diagnostics, which limits their adoption in resource-constrained regions. The urgency for these testing solutions remains critical due to the substantial burden of resistant pathogens. According to the World Health Organization, in 2024, it was estimated that approximately 136 million antibiotic-resistant healthcare-associated infections occur globally every year.

Key Market Drivers

Technological advancements in rapid diagnostic methodologies are fundamentally reshaping the Global Hospital Acquired Disease Testing Market by enabling earlier and more accurate pathogen identification. The transition from traditional culture-based methods to advanced molecular diagnostics, particularly syndromic testing, allows clinicians to detect multiple infectious agents simultaneously within hours rather than days. This capability is vital for initiating appropriate antimicrobial therapy promptly, thereby improving patient outcomes and optimizing hospital resources. The commercial success of these innovations underscores their growing adoption; for instance, according to bioMérieux, September 2024, in the 'First-Half 2024 Financial Results', sales of the company’s BIOFIRE non-respiratory panels, which are critical for diagnosing hospital-associated conditions like sepsis and meningitis, grew by 19% organically.

Concurrently, the rising threat of multidrug-resistant pathogens is intensifying the demand for these sophisticated testing solutions as healthcare facilities struggle to contain superbugs. As resistance mechanisms evolve, the inability of standard antibiotics to treat common infections necessitates precise diagnostics to guide antimicrobial stewardship and prevent outbreaks. The urgency of this issue is highlighted by long-term projections; according to Wellcome, September 2024, in the 'Global burden of bacterial antimicrobial resistance' report, it is forecast that more than 39 million deaths will be directly attributable to antibiotic-resistant infections between 2025 and 2050. Furthermore, recent surveillance data confirms the immediate escalation of specific threats. According to the Centers for Disease Control and Prevention, July 2024, in the 'Antimicrobial Resistance Threats in the United States' update, the number of reported clinical cases of Candida auris, a multidrug-resistant fungus spreading in healthcare facilities, increased nearly five-fold from 2019 to the most recent reporting period.

Download Free Sample Report

Key Market Challenges

The high cost associated with advanced molecular diagnostics presents a substantial impediment to the expansion of the Global Hospital Acquired Disease Testing Market. Healthcare institutions, especially those in resource-constrained environments, frequently face difficult trade-offs between acquiring advanced screening tools and managing fundamental operational expenses. As a result, the adoption of precise but expensive molecular assays is restricted, forcing many providers to rely on traditional, less costly diagnostic methods that may delay appropriate treatment and infection control measures.

This financial limitation is substantiated by low investment levels in diagnostic technologies relative to overall health expenditures. The market struggles to grow when budgetary allocations for testing remain disproportionately small compared to other healthcare verticals. According to MedTech Europe, in 2024, the expenditure on in vitro diagnostics was estimated to comprise only 0.6% of total healthcare spending. This figure highlights the severe budgetary constraints that hamper the uptake of advanced testing solutions. Without the fiscal capacity to invest in these higher-priced diagnostics, the market cannot fully capitalize on the demand driven by the prevalence of infectious diseases.

Key Market Trends

The proliferation of Point-of-Care (POC) testing capabilities is decentralizing the detection of hospital-acquired diseases, allowing healthcare providers to identify pathogens at the bedside rather than relying solely on central laboratories. This shift reduces turnaround times significantly, facilitating immediate isolation and treatment decisions that are crucial for containing outbreaks in high-risk wards. The market impact of this trend is evident in the rapid commercial uptake of decentralized molecular platforms that offer lab-quality results in non-laboratory settings. According to bioMérieux, March 2025, in the '2024 Financial Results', the company reported that sales of its SPOTFIRE point-of-care solution accelerated to reach €95 million for the year, driven by a growing installed base across healthcare facilities.

Simultaneously, there is a marked shift towards real-time digital surveillance systems designed to track infection rates and antimicrobial resistance patterns across healthcare networks. These systems aggregate data from surgical procedures and inpatient stays to identify high-risk areas and monitor compliance with infection control protocols, thereby creating a continuous feedback loop for hospital administrators. The increasing participation in national and regional tracking programs is fueling the demand for consistent testing and rigorous data reporting standards. According to the UK Health Security Agency, December 2025, in the 'Surveillance of surgical site infections in NHS hospitals in England: 2024 to 2025 annual report', the volume of surgical procedures submitted for surveillance analysis increased by 7.9% compared to the previous year, reflecting heightened adherence to monitoring mandates.

Segmental Insights

The Molecular Tests segment is currently the fastest-growing area within the Global Hospital Acquired Disease Testing Market, primarily driven by the demand for higher sensitivity and rapid turnaround times. Technologies such as Polymerase Chain Reaction allow for the precise identification of pathogens and antimicrobial resistance markers much faster than conventional culture-based methods. This capability enables medical professionals to promptly administer appropriate therapies and contain outbreaks. Additionally, the U.S. FDA has increasingly granted clearances for advanced molecular platforms, further encouraging healthcare facilities to adopt these efficient diagnostic solutions for better patient management.

Regional Insights

Europe maintains a leading position in the hospital-acquired disease testing market, driven by stringent government regulations and a centralized focus on infection control. This dominance is largely attributed to the proactive surveillance and prevention mandates established by the European Centre for Disease Prevention and Control. These guidelines compel healthcare facilities to implement rigorous testing protocols for the early detection and containment of infections. Additionally, the region benefits from publicly funded healthcare systems that prioritize patient safety standards, ensuring the consistent adoption of diagnostic solutions throughout the European medical sector.

Recent Developments

• In June 2025, bioMérieux announced an agreement to acquire the assets of Day Zero Diagnostics, a company specializing in genomic sequencing and machine learning for infectious disease diagnosis. This strategic acquisition was intended to bolster the company's capabilities in next-generation sequencing and rapid diagnostic solutions for fighting antibiotic-resistant infections in hospitals. The deal included the acquisition of workflows and proprietary technologies that enable the identification of pathogen species and resistance profiles directly from blood samples. The company's management highlighted that this investment aligned with their long-term commitment to advancing antimicrobial stewardship and public health.
• In November 2024, Pattern Bioscience announced that it had been awarded a contract worth up to $40.9 million by the Biomedical Advanced Research and Development Authority (BARDA). The initial award of $22.5 million was allocated to support the late-stage development and clinical validation of the company's single-cell microbiology platform for rapid diagnosis of pneumonia and bacteremia. This technology aimed to identify bacterial pathogens and their antibiotic susceptibility profiles in hours rather than days. The company's leadership emphasized that this funding would accelerate the availability of their testing platform in critical care settings to combat antimicrobial resistance.
• In February 2024, Selux Diagnostics received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Positive Blood Culture (PBC) Separator. This proprietary technology was designed to prepare samples for antibiotic susceptibility testing directly from positive blood cultures, thereby streamlining the workflow for microbiology laboratories. The device allowed for the rapid separation of microorganisms from blood samples, facilitating faster results for patients with bloodstream infections. The company’s Chief Executive Officer noted that this regulatory milestone represented a significant advancement in infectious disease care by enabling quicker targeted therapy decisions in hospital settings.
• In February 2024, T2 Biosystems announced that it had obtained FDA 510(k) clearance for an expansion of its T2Bacteria Panel to include the detection of Acinetobacter baumannii. This bacterial pathogen is frequently associated with hospital-acquired infections, particularly in intensive care units, and is known for high mortality rates and antibiotic resistance. The updated panel allowed clinicians to detect this critical pathogen directly from whole blood samples within three to five hours, significantly faster than traditional culture-based methods. The company stated that this enhancement covered approximately 75% of sepsis-causing bacterial pathogens commonly found in bloodstream infections.

Key Market Players

• bioMérieux SA
• Abbott Laboratories Inc.
• F. Hoffmann-La Roche Ltd.
• Siemens Healthcare Private Limited
• Becton, Dickinson and Company
• Bioscience, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc
• Hologic, Inc.
• Meridian Bioscience, Inc

By Test Type	By Infection Type	By Product	By Type	By Region
Molecular Conventional	UTI Pneumonia Surgical Site Infection Blood Stream Infections Others	Consumables Instruments	Blood Tests Urinalysis	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Hospital Acquired Disease Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Hospital Acquired Disease Testing Market, By Test Type:

• Molecular
• Conventional

• Hospital Acquired Disease Testing Market, By Infection Type:

• UTI
• Pneumonia
• Surgical Site Infection
• Blood Stream Infections
• Others

• Hospital Acquired Disease Testing Market, By Product:

• Consumables
• Instruments

• Hospital Acquired Disease Testing Market, By Type:

• Blood Tests
• Urinalysis

• Hospital Acquired Disease Testing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE